Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Privately held company Antipodean Pharmaceuticals has completed enrollment in a phase II study to evaluate its lead compound MitoQ in Parkinson's disease.
Subscribe to our email newsletter
“MitoQ blocks the effects of oxidation, a chemical reaction that generates oxygen free radicals, which can attack and destroy cells. We achieved enrollment in this phase II trial ahead of schedule, demonstrating the rapid advancement of our clinical programs,” said Ken Taylor, CEO of Antipodean Pharmaceuticals.
The clinical trial is evaluating patients who have met the diagnosis criteria for Parkinson’s, but have not begun any treatment. Patients were randomized into one of three treatment arms to compare treatment with MitoQ at 40 mg and 80 mg to placebo, orally administered once daily. The primary endpoint is disease progression. An independent data safety monitoring board is reviewing safety data periodically.
“Several neurodegenerative disorders, including Parkinson’s, are associated with mitochondrial dysfunction from oxidative damage,” said Dr Barry Snow, head of Department of Neurology, Auckland Hospital. “MitoQ may be able to stem the progression of these difficult-to-treat conditions.”